Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novo Nordisk Licenses Adimab Tech Transfer Program | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novo Nordisk Licenses Adimab Tech Transfer Program

Will use platform for the discovery and optimization of antibodies

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adimab, LLC has licensed its technology transfer program to Novo Nordisk and will receive upfront payments, annual licensing fees and royalties on commercialized products. Novo Nordisk has been granted a non-exclusive license to use Adimab’s antibody platform for the discovery and optimization of antibodies.
 
“We are pleased to have expanded our partnership with Novo Nordisk,” said Tillman Gerngross, chief executive officer and co-founder of Adimab. “This is the third platform transfer this year, and this transaction with Novo Nordisk further validates our view that leading pharma companies have a need for better antibody discovery and optimization tools. At this point in time, our platform is the leading technology for antibody discovery and optimization, but, we haven’t rested on our laurels; we have over 25 people working on improving and expanding the platform’s capabilities to make sure that we stay ahead of the field.”
 
“We are very pleased to have established a broad relationship with Adimab,” said Hanne Risager Romedahl, vice president of Novo Nordisk. “We feel confident that Adimab offers a comprehensive solution for our antibody discovery needs. In addition to using the platform as a rapid IgG discovery engine, we are particularly impressed with the ability to optimize antibodies with this broad protein engineering tool. This capability will nicely complement and enhance our existing antibody discovery technologies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics